Evidence map›Paper›PMID 37758193›Full record

Trial reportNeuro-oncology2024

A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.

Atsuro Saijo, Hirokazu Ogino, Nicholas A Butowski, Meghan R Tedesco, David Gibson, Payal B Watchmaker, Kaori Okada, Albert S Wang, Anny Shai, Andres M Salazar and 16 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02924038 (Pilot Randomized Neo-adjuvant Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02924038 phase1terminatednot on this map

Pilot Randomized Neo-adjuvant Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

TypeinterventionalSponsorNicholas ButowskiRan2017 to 2022Enrolled14ConditionsGlioma, Malignant Glioma, Astrocytoma, Grade II, OligodendrogliomaArmsIMA950, poly-ICLC, Varlilumab
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 4 institutions in 3 countries.

Atsuro SaijoDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.ORCID 0000-0002-7710-5498
Hirokazu OginoDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Nicholas A ButowskiDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Meghan R TedescoDepartment of Neurology, University of California, San Francisco, CA, USA.
David GibsonDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Payal B WatchmakerDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Kaori OkadaDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Albert S WangDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Anny ShaiDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Andres M SalazarOncovir Inc., Washington, DC, USA.
Annette M MolinaroDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Jane E RabbittDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Maryam ShahinDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Arie PerryDepartment of Pathology, University of California, San Francisco, CA, USA.
Jennifer L ClarkeDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.ORCID 0000-0002-8054-7342
Jennie W TaylorDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.ORCID 0000-0003-3980-5626
Mariza DarasDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Nancy Ann Oberheim BushDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Shawn L Hervey-JumperDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Joanna J PhillipsDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Susan M ChangDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Norbert HilfImmatics Biotechnologies GmbH, Tuebingen, Germany.
Andrea Mayer-MoklerHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Tibor KelerCelldex Theraepeutics, Inc., Hampton, NJ, USA.
Mitchel S BergerDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.
Hideho OkadaDepartment of Neurological Surgery, University of California, San Francisco, CA, USA.ORCID 0000-0003-0076-9920
University of California, San Francisco · USCelldex Therapeutics (United States) · USImmatics Biotechnologies (Germany) · DEOncovir (United States) · US

Funding

Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Susan M Chang · 2002 to 2026
$57.4M
Preclinical development of breakthrough immunotherapy for brain tumorsR35NS105068 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKADA, HIDEHO · 2018 to 2025
$6.0M
Pilot randomized neoadjuvant vaccine with CD27-costimulation in low-grade gliomaR21CA233856 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OKADA, HIDEHO · 2019 to 2020
$318k
NCI NIH HHS P50 CA097257NCI NIH HHS R21 CA233856NIH HHS 1R35NS105068NINDS NIH HHS R35 NS105068
6 · The paper itself

Abstract

backgroundCentral nervous system (CNS) WHO grade 2 low-grade glioma (LGG) patients are at high risk for recurrence and with unfavorable long-term prognosis due to the treatment resistance and malignant transformation to high-grade glioma. Considering the relatively intact systemic immunity and slow-growing nature, immunotherapy may offer an effective treatment option for LGG patients.

methodsWe conducted a prospective, randomized pilot study to evaluate the safety and immunological response of the multipeptide IMA950 vaccine with agonistic anti-CD27 antibody, varlilumab, in CNS WHO grade 2 LGG patients. Patients were randomized to receive combination therapy with IMA950 + poly-ICLC and varlilumab (Arm 1) or IMA950 + poly-ICLC (Arm 2) before surgery, followed by adjuvant vaccines.

resultsA total of 14 eligible patients were enrolled in the study. Four patients received pre-surgery vaccines but were excluded from postsurgery vaccines due to the high-grade diagnosis of the resected tumor. No regimen-limiting toxicity was observed. All patients demonstrated a significant increase of anti-IMA950 CD8+ T-cell response postvaccine in the peripheral blood, but no IMA950-reactive CD8+ T cells were detected in the resected tumor. Mass cytometry analyses revealed that adding varlilumab promoted T helper type 1 effector memory CD4+ and effector memory CD8+ T-cell differentiation in the PBMC but not in the tumor microenvironment.

conclusionThe combinational immunotherapy, including varlilumab, was well-tolerated and induced vaccine-reactive T-cell expansion in the peripheral blood but without a detectable response in the tumor. Further developments of strategies to overcome the blood-tumor barrier are warranted to improve the efficacy of immunotherapy for LGG patients.

Indexed as

Antibodies, Monoclonal, HumanizedCancer VaccinesGliomaPeptidesCell DifferentiationHumansLeukocytes, MononuclearPilot ProjectsProspective StudiesTumor MicroenvironmentAntibodies, Monoclonal, HumanizedCancer VaccinesIMA950PeptidesvarlilumabIMA950immunotherapylow-grade gliomapoly-ICLCvarlilumab

Identifiers

PMID37758193
PMCPMC10836773
OpenAlexW4387080083

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.